FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease

by Raja Nandhini on  March 7, 2013 at 6:12 AM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Johnson & Johnson (JNJ) and its partner Bayer AG (BAYN) suffered a blow when FDA rejected for the second time the extended use of Xarelto, a blood thinner, to treat heart disease and reduce the risk of heart attacks.
 FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease
FDA for the Second Time Rejects Blood Thinner, Xarelto, for Heart Disease

Xarelto is an approved drug to prevent blood clots in patients undergoing hip and knee surgeries and to prevent stroke in patients with irregular heartbeats.

Earlier in July 2012, FDA had denied the approval to use Xarelto on heart patients stating missing data of around 1000 patients towards the end of the study.

On tracking down the data from patients who withdrew from the study, the overall results were positive. The drug when used with other regular drugs had the efficiency to reduce the risk of death due to heart disease by 16%.

However, the risk of bleeding increased by nearly four times, which outweighed the efficacy of Xarelto in preventing heart attacks. This has greatly influenced FDA's decision to reject the blood thinner to treat heart patients.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Thalassemia Cardiac Catheterization Heart Attack Air travel: To fly or not to fly Diet Lifestyle and Heart Disease Silent Killer Diseases Heart Healthy Heart Statins Mitral Valve Prolapse 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...